<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001655'>Patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) and <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo> (<z:chebi fb="37" ids="15365">ASA</z:chebi>) have been associated with <z:hpo ids='HP_0001297'>stroke</z:hpo> in young adults </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:mp ids='MP_0004225'>PFO</z:mp> suffering from <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> are at increased risk for recurrent events </plain></SENT>
<SENT sid="2" pm="."><plain>Percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure is a new treatment modality aimed at secondary prevention </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Since April 1994, 132 consecutive patients, aged 51 +/- 12 years with <z:mp ids='MP_0004225'>PFO</z:mp> and with at least one paradoxical embolic event, underwent percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure using six different device types </plain></SENT>
<SENT sid="4" pm="."><plain>The embolic index event was an <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in 62% of patients, a <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) in 33% of patients, and a peripheral embolism in 5% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-six (27%) patients had <z:mp ids='MP_0004225'>PFO</z:mp> associated with <z:chebi fb="37" ids="15365">ASA</z:chebi>, whereas 96 (73%) patients had <z:mp ids='MP_0004225'>PFO</z:mp> only </plain></SENT>
<SENT sid="6" pm="."><plain>The implantation procedure was successful in 130 (98%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>During and up to 6 years of follow-up (mean 1.8 +/- 1.6 years, 231 patient years), a total of eight recurrent embolic events were observed, with six <z:hpo ids='HP_0002326'>TIAs</z:hpo>, two peripheral emboli, and no <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The actuarial freedom from recurrence of the combined end point of <z:hpo ids='HP_0002326'>TIA</z:hpo>, <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, and peripheral embolism was 95.3% (95% confidence interval [CI], 91.0%-96.4%) at 1 year and 90.5% (95% CI, 83.6%-97.2%) at 6 years </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure can be performed with a high success rate </plain></SENT>
<SENT sid="10" pm="."><plain>The procedure appears a promising therapeutic modality for secondary prevention of recurrent embolism in patients with <z:mp ids='MP_0004225'>PFO</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Randomized trials must define its therapeutic value </plain></SENT>
</text></document>